Need help finding what you are looking for?
Contact Us
PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1514003
PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1514003
Huntington's Disease Therapeutics
PUBLISHED:
PAGES: 172 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
Global Huntington's Disease Therapeutics Market to Reach US$20.0 Billion by 2030
The global market for Huntington's Disease Therapeutics estimated at US$2.9 Billion in the year 2023, is expected to reach US$20.0 Billion by 2030, growing at a CAGR of 31.5% over the analysis period 2023-2030.
The U.S. Market is Estimated at US$787.6 Million While China is Forecast to Grow at 40.2% CAGR
The Huntington's Disease Therapeutics market in the U.S. is estimated at US$787.6 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$5.6 Billion by the year 2030 trailing a CAGR of 40.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 25.0% and 28.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 26.6% CAGR.
Huntington's Disease Therapeutics - Key Trends and Drivers
Huntington’s disease (HD) is a progressive neurodegenerative disorder characterized by motor dysfunction, cognitive decline, and psychiatric symptoms. It is caused by a genetic mutation in the HTT gene, leading to the production of an abnormal huntingtin protein that progressively damages neurons in specific regions of the brain. Currently, there is no cure for Huntington’s disease, and treatment strategies are primarily focused on managing symptoms and improving patients' quality of life. Therapeutics for HD include medications for motor symptoms, such as tetrabenazine and deutetrabenazine, which help control chorea (involuntary movements), and antipsychotic drugs to manage psychiatric symptoms. Additionally, antidepressants and mood stabilizers are often prescribed to address the emotional and behavioral aspects of the disease. Despite these symptomatic treatments, there remains a significant unmet need for disease-modifying therapies that can slow or halt the progression of HD.
Research and development in Huntington’s disease therapeutics have made notable advancements in recent years, driven by a deeper understanding of the disease’s genetic and molecular mechanisms. Innovative therapeutic approaches are being explored, including gene therapies aimed at silencing the mutated HTT gene, antisense oligonucleotides (ASOs) designed to reduce the production of the toxic huntingtin protein, and small molecule inhibitors targeting various pathways involved in neuronal degeneration. Notably, clinical trials for gene-editing technologies, such as CRISPR/Cas9, and RNA interference (RNAi) therapies are underway, showing promise in preclinical studies. Furthermore, stem cell research is being investigated as a potential strategy for replacing damaged neurons and restoring neurological function. These cutting-edge therapies, while still in experimental stages, represent a hopeful future for altering the course of Huntington’s disease.
The growth in the Huntington’s disease therapeutics market is driven by several factors, including technological advancements in genetic research, increased funding for neurodegenerative disease research, and a growing awareness of HD. The progress in gene therapy and RNA-based technologies has opened new avenues for developing treatments that target the root cause of the disease rather than just managing symptoms. Investment from pharmaceutical companies and biotech firms into HD research has accelerated the development of potential therapies, with several promising candidates advancing through clinical trials. Additionally, patient advocacy groups and research organizations are playing a crucial role in raising awareness and securing funding for HD research. The regulatory environment is also becoming more supportive, with initiatives aimed at expediting the approval process for orphan drugs and breakthrough therapies. Advances in diagnostic technologies, including the use of biomarkers for early detection and monitoring of disease progression, are facilitating more timely and precise treatment interventions. Collectively, these factors are driving significant growth and innovation in the Huntington’s disease therapeutics market, offering hope for more effective treatments and improved outcomes for patients in the near future.
Select Competitors (Total 23 Featured) -
- Alnylam Pharmaceuticals, Inc.
- Evotec AG
- GlaxoSmithKline PLC
- Horizon Therapeutics plc
- Ionis Pharmaceuticals, Inc.
- Raptor Pharmaceutical Corporation
- Sangamo Biosciences, Inc.
- Suven Life Sciences Ltd.
- Teva Pharmaceutical Industries Ltd.
- Vertex Pharmaceuticals Inc.
- Wave Life Sciences Ltd.
Product Code: MCP-6280
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
- 1. MARKET OVERVIEW
- Influencer Market Insights
- Global Economic Update
- Huntington's Disease Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
- 2. FOCUS ON SELECT PLAYERS
- 3. MARKET TRENDS & DRIVERS
- Advances in Genetic Research Throws the Spotlight on Huntington's Disease Therapies
- Technological Innovations in Gene Therapy Propel Growth in Treatment Options
- Focus on Neurodegenerative Disease Research Expands Addressable Market Opportunity
- Development of Antisense Oligonucleotides (ASOs) Strengthens Business Case for Targeted Therapies
- Emerging RNA Interference (RNAi) Technologies Drives Adoption of Novel Treatment Approaches
- Promising Results from Stem Cell Research Generates Hope for Neuronal Restoration
- CRISPR/Cas9 and Gene-Editing Techniques: Here's the Story of Revolutionary Therapeutic Potential
- Growing Awareness and Advocacy Efforts Spurring Growth in Research and Development
- Regulatory Initiatives for Orphan Drugs Accelerates Demand for Huntington's Disease Treatments
- Advances in Biomarker Development Drives Adoption of Early Detection and Monitoring Tools
- Progress in Disease-Modifying Therapies to Transform Patient Outcomes
- Expedited Clinical Trials for Breakthrough Therapies Generates Momentum in Market Dynamics
- Expansion of Early-Stage Clinical Programs: Here's the Story of Future Therapeutic Advancements
- 4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Huntington's Disease Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
- TABLE 2: World Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 3: World Historic Review for Huntington's Disease Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 4: World 16-Year Perspective for Huntington's Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
- UNITED STATES
- Huntington's Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
- TABLE 5: USA Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 6: USA Historic Review for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- CANADA
- TABLE 7: Canada Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 8: Canada Historic Review for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- JAPAN
- Huntington's Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
- TABLE 9: Japan Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 10: Japan Historic Review for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- CHINA
- Huntington's Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
- TABLE 11: China Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 12: China Historic Review for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- EUROPE
- Huntington's Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
- TABLE 13: Europe Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 14: Europe Historic Review for Huntington's Disease Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 15: Europe 16-Year Perspective for Huntington's Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
- FRANCE
- Huntington's Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
- TABLE 16: France Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 17: France Historic Review for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- GERMANY
- Huntington's Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
- TABLE 18: Germany Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 19: Germany Historic Review for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- ITALY
- TABLE 20: Italy Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 21: Italy Historic Review for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- UNITED KINGDOM
- Huntington's Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
- TABLE 22: UK Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 23: UK Historic Review for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- SPAIN
- TABLE 24: Spain Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 25: Spain Historic Review for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- RUSSIA
- TABLE 26: Russia Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 27: Russia Historic Review for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- REST OF EUROPE
- TABLE 28: Rest of Europe Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 29: Rest of Europe Historic Review for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- ASIA-PACIFIC
- Huntington's Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
- TABLE 30: Asia-Pacific Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 31: Asia-Pacific Historic Review for Huntington's Disease Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 32: Asia-Pacific 16-Year Perspective for Huntington's Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
- AUSTRALIA
- Huntington's Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
- TABLE 33: Australia Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 34: Australia Historic Review for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- INDIA
- Huntington's Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
- TABLE 35: India Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 36: India Historic Review for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- SOUTH KOREA
- TABLE 37: South Korea Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 38: South Korea Historic Review for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- REST OF ASIA-PACIFIC
- TABLE 39: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 40: Rest of Asia-Pacific Historic Review for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- LATIN AMERICA
- Huntington's Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
- TABLE 41: Latin America Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 42: Latin America Historic Review for Huntington's Disease Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 43: Latin America 16-Year Perspective for Huntington's Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
- ARGENTINA
- TABLE 44: Argentina Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 45: Argentina Historic Review for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- BRAZIL
- TABLE 46: Brazil Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 47: Brazil Historic Review for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- MEXICO
- TABLE 48: Mexico Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 49: Mexico Historic Review for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- REST OF LATIN AMERICA
- TABLE 50: Rest of Latin America Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 51: Rest of Latin America Historic Review for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- MIDDLE EAST
- Huntington's Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
- TABLE 52: Middle East Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 53: Middle East Historic Review for Huntington's Disease Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 54: Middle East 16-Year Perspective for Huntington's Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
- IRAN
- TABLE 55: Iran Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 56: Iran Historic Review for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- ISRAEL
- TABLE 57: Israel Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 58: Israel Historic Review for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- SAUDI ARABIA
- TABLE 59: Saudi Arabia Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 60: Saudi Arabia Historic Review for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- UNITED ARAB EMIRATES
- TABLE 61: UAE Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 62: UAE Historic Review for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- REST OF MIDDLE EAST
- TABLE 63: Rest of Middle East Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 64: Rest of Middle East Historic Review for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- AFRICA
- Huntington's Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
- TABLE 65: Africa Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 66: Africa Historic Review for Huntington's Disease Therapeutics by Segment - Huntington's Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
IV. COMPETITION
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.